《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》免疫功能状态评估部分解读

doi:10.19982/j.issn.1000-6621.20220421

中国防痨杂志 ›› 2023, Vol. 45 ›› Issue (2): 134-138.doi: 10.19982/j.issn.1000-6621.20220421

《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》免疫功能状态评估部分解读

薛勇, 吴雪琼()

中国人民解放军总医院第八医学中心结核病医学部研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室,北京 100091

收稿日期:2022-11-11 出版日期:2023-02-10 发布日期:2023-02-01
通信作者: 吴雪琼 E-mail:xueqiongwu@139.com
基金资助:
高水平结核检验平台和科研平台的建设(A3705012013);军队结核潜伏感染高危人群的早期识别和防护干预新技术的研究(18CXZ028)

Interpretation of immune function status assessment in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition)

Xue Yong, Wu Xueqiong()

Tuberculosis Prevention and Control Key Laboratory, Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute for Tuberculosis Research, the 8th Medical Center of Chinese PLA General Hospital, Beijing 100091, China

Received:2022-11-11 Online:2023-02-10 Published:2023-02-01
Contact: Wu Xueqiong E-mail:xueqiongwu@139.com
Supported by:
Construction of High Level Tuberculosis Test Platform and Scientific Research Platform(A3705012013);Research Project of New Technologies for Early Identification and Prevention and Intervention of High-risk Groups with Latent Tuberculosis Infection in the Military(18CXZ028)

摘要/Abstract

摘要：

越来越多的临床证据表明结核病不只是一种感染性疾病,也是一种免疫性疾病。许多活动性结核病患者存在免疫功能低下,因此,对其进行免疫功能状态评估十分必要,可为临床免疫干预提供依据。发表于《中国防痨杂志》2022年第1期的《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》,为结核病患者进行免疫功能状态评估和免疫辅助治疗提供了建议,并形成共识。笔者针对共识中免疫功能状态评估部分进行解读,为读者介绍在共识之外更多的免疫评价新进展,以丰富读者对结核病患者免疫功能评估的认识。

关键词: 结核, 免疫测定, 总结性报告(主题)

Abstract:

More and more clinical evidence showed that tuberculosis is not only an infectious disease, but also an immune disease. Many patients with active tuberculosis have the low immune function, so it is important and necessary to evaluate their immune function status, which can provide a basis for clinical immune intervention. Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition) published in Issue 1 of 2022 in the Chinese Journal of Antituberculosis, provides recommendations for the evaluation of immune function status and immunotherapy in tuberculosis patients, and forms a consensus. This interpretation mainly focuses on the assessment of immune function status, introduces more new progress of immune evaluation beyond the consensus for the readers, and enriches readers’ understanding of immune function assessment in tuberculosis patients.

Key words: Tuberculosis, Immunoassay, Consensus development conferences as topic

中图分类号:

薛勇, 吴雪琼. 《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》免疫功能状态评估部分解读[J]. 中国防痨杂志, 2023, 45(2): 134-138. doi: 10.19982/j.issn.1000-6621.20220421

Xue Yong, Wu Xueqiong. Interpretation of immune function status assessment in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition)[J]. Chinese Journal of Antituberculosis, 2023, 45(2): 134-138. doi: 10.19982/j.issn.1000-6621.20220421

参考文献 26

[1]	中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版). 中国防痨杂志, 2022, 44(1): 9-27. doi:10.19982/j.issn.1000-6621.20210680. doi: 10.19982/j.issn.1000-6621.20210680
[2]	Nakao M, Muramatsu H, Arakawa S, et al. Immunonutritional status and pulmonary cavitation in patient with tuberculosis: A revisit with an assessment of neutrophil/lymphocyte ratio. Respir Investig, 2019, 57(1): 60-66. doi:10.1016/j.resinv.2018.08.007. doi: 10.1016/j.resinv.2018.08.007 URL
[3]	Jeon YL, Lee WI, Kang SY, et al. Neutrophil-to-Monocyte-Plus-Lymphocyte Ratio as a Potential Marker for Discriminating Pulmonary Tuberculosis from Nontuberculosis Infectious Lung Diseases. Lab Med, 2019, 50(3): 286-291. doi:10.1093/labmed/lmy083. doi: 10.1093/labmed/lmy083 pmid: 30753566
[4]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础专业和临床专业学术部. 结核病患者外周血淋巴细胞亚群检测及临床应用专家共识. 中国防痨杂志, 2020, 42(10): 1009-1016. doi:10.3969/j.issn.1000-6621.2020.10.001. doi: 10.3969/j.issn.1000-6621.2020.10.001
[5]	Hally KE, Ferrer-Font L, Pilkington KR, et al. OMIP 083: A 21-marker 18-color flow cytometry panel for in-depth phenotyping of human peripheral monocytes. Cytometry A, 2022, 101(5): 374-379. doi:10.1002/cyto.a.24545. doi: 10.1002/cyto.a.24545 URL
[6]	Castaño D, García LF, Rojas M. Increased frequency and cell death of CD16⁺ monocytes with Mycobacterium tuberculosis infection. Tuberculosis (Edinb), 2011, 91(5): 348-360. doi:10.1016/j.tube.2011.04.002. doi: 10.1016/j.tube.2011.04.002 URL
[7]	曹雪涛, 姚智, 熊思东, 等. 医学免疫学. 7版. 北京: 人民卫生出版社, 2018: 109-118.
[8]	Estévez O, Anibarro L, Garet E, et al. Multi-parameter flow cytometry immunophenotyping distinguishes different stages of tuberculosis infection. J Infect, 2020, 81(1): 57-71. doi:10.1016/j.jinf.2020.03.064. doi: S0163-4453(20)30218-8 pmid: 32330526
[9]	Ndishimye P, Zakham F, Musanabaganwa C, et al. CD4⁺ regulatory T cells and CD4⁺ activated T cells in new active and relapse tuberculosis. Cell Mol Biol (Noisy-le-grand), 2019, 65(8): 18-22.
[10]	Qin S, Chen R, Jiang YJ, et al. Multifunctional T cell response in active pulmonary tuberculosis patients. Int Immunopharmacol, 2021, 99: 107898. doi:10.1016/j.intimp.2021.107898. doi: 10.1016/j.intimp.2021.107898 URL
[11]	Okada R, Kondo T, Matsuki F, et al. Phenotypic classification of human CD4⁺ T cell subsets and their differentiation. Int Immunol, 2008, 20(9): 1189-1199. doi:10.1093/intimm/dxn075. doi: 10.1093/intimm/dxn075 pmid: 18635582
[12]	Harari A, Dutoit V, Cellerai C, et al. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev, 2006, 211: 236-254. doi:10.1111/j.0105-2896.2006.00395.x. doi: 10.1111/j.0105-2896.2006.00395.x pmid: 16824132
[13]	Priyanto H, Chua E, Hutchinson P, et al. A decrease in PPD specific CD4 T cell CD38 and HLA-DR expression in pulmonary tuberculosis patients after 8 weeks of therapy correlates with successful anti-tuberculosis treatment. J Clin Tuberc Other Mycobact Dis, 2021, 22: 100214. doi:10.1016/j.jctube.2021.100214. doi: 10.1016/j.jctube.2021.100214
[14]	Luo Y, Xue Y, Mao L, et al. Activation Phenotype of Mycobacterium tuberculosis-Specific CD4⁺ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection. Front Immunol, 2021, 12: 721013. doi:10.3389/fimmu.2021.721013. doi: 10.3389/fimmu.2021.721013 URL
[15]	Adekambi T, Ibegbu CC, Cagle S, et al. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest, 2015, 125(5): 1827-1838. doi:10.1172/JCI77990. doi: 10.1172/JCI77990 pmid: 25822019
[16]	Luo Y, Xue Y, Tang GX, et al. Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection. Front Immunol, 2021, 12: 658843. doi:10.3389/fimmu.2021.658843. doi: 10.3389/fimmu.2021.658843 URL
[17]	Kiran B, Cagatay T, Clark P, et al. Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis? Arch Med Sci, 2010, 6(1): 77-82. doi:10.5114/aoms.2010.13511. doi: 10.5114/aoms.2010.13511 pmid: 22371724
[18]	Bernal-Fernandez G, Espinosa-Cueto P, Leyva-Meza R, et al. Decreased expression of T-cell costimulatory molecule CD 28 on CD4 and CD8 T cells of mexican patients with pulmonary tuberculosis. Tuberc Res Treat, 2010, 2010: 517547. doi:10.1155/2010/517547. doi: 10.1155/2010/517547
[19]	Vickers MA, Darboe F, Muefong CN, et al. Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers. Front Immunol, 2020, 11: 572620. doi:10.3389/fimmu.2020.572620. doi: 10.3389/fimmu.2020.572620 URL
[20]	Wang X, Liang KD, Zhang JA, et al. Increased B cell activating factor is associated with B cell class switching in patients with tuberculous pleural effusion. Mol Med Rep, 2018, 18(2): 1704-1709. doi:10.3892/mmr.2018.9073. doi: 10.3892/mmr.2018.9073 pmid: 29845274
[21]	Morais-Papini TF, Coelho-Dos-Reis JGA, Wendling APB, et al. Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection. Immunobiology, 2017, 222(11): 1014-1024. doi:10.1016/j.imbio.2017.05.016. doi: S0171-2985(17)30099-2 pmid: 28619539
[22]	Jean Bosco M, Wei M, Hou H, et al. The exhausted CD4⁺CXCR5⁺ T cells involve the pathogenesis of human tuberculosis disease. Int J Infect Dis, 2018, 74: 1-9. doi:10.1016/j.ijid.2018.06.011. doi: 10.1016/j.ijid.2018.06.011 URL
[23]	An HR, Bai XJ, Liang JQ, et al. The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis. Clin Respir J, 2022, 16(5): 369-379. doi:10.1111/crj.13490. doi: 10.1111/crj.13490 URL
[24]	Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a syste-matic review. Int J Infect Dis, 2011, 15(9): e594-e600. doi:10.1016/j.ijid.2011.05.002. doi: 10.1016/j.ijid.2011.05.002
[25]	Seneviratne SL, Doffinger R, Macfarlane J, et al. Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy. Thorax, 2007, 62(1): 97-99. doi:10.1136/thx.2005.051649. doi: 10.1136/thx.2005.051649 pmid: 17189534
[26]	Zhang R, Xi X, Wang C, et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis. PLoS One, 2018, 13(7): e0201025. doi:10.1371/journal.pone.0201025. doi: 10.1371/journal.pone.0201025

《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》免疫功能状态评估部分解读

Interpretation of immune function status assessment in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition)

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	张梦娴, 王倪, 黄飞, 周丽平, 赵雁林. 中国结核病疫苗研发现状及展望[J]. 中国防痨杂志, 2023, 45(2): 125-129.
[2]	郭同磊, 曹雪芳, 高磊. 《结核分枝杆菌重组蛋白皮肤试验操作规范》解读[J]. 中国防痨杂志, 2023, 45(2): 130-133.
[3]	刘荣梅, 吕子征, 马丽萍, 李强, 宋艳华, 陈红梅, 孔忠顺, 高孟秋. 粪便GeneXpert MTB/RIF检测在肠结核诊断中的应用价值[J]. 中国防痨杂志, 2023, 45(2): 139-143.
[4]	田丽丽, 陈双双, 樊瑞芳, 张洁, 王嫩寒, 陈昊, 代小伟, 任怡宣, 赵琰枫, 李传友, 丁北川, 李波, 于兰, 易俊莉, 王佩, 杨新宇, 宋卫萍. 四种方法联合检测对病原学阴性肺结核的诊断价值[J]. 中国防痨杂志, 2023, 45(2): 144-150.
[5]	杜艳妮, 薛明, 关春爽, 邢玉雪, 陈步东, 谢汝明. 艾滋病合并肺结核患者胸部CT不典型影像表现分析[J]. 中国防痨杂志, 2023, 45(2): 159-164.
[6]	王红红, 郭少晨, 周文强, 刘忠泉, 朱慧, 陆宇. 耐药结核病患者利奈唑胺血药浓度对血液系统毒性发生的影响[J]. 中国防痨杂志, 2023, 45(2): 165-171.
[7]	杨虹, 马进宝, 任斐, 李荣, 武延琴, 张耀辉. 15例耐药肺结核患者家庭接触者发展为活动性肺结核的临床特征分析[J]. 中国防痨杂志, 2023, 45(2): 172-180.
[8]	刘思敏, 李巧梅, 唐佳宜, 李婷婷, 丁国武. 基于年龄-时期-队列模型分析中国0~10岁人群肺结核发病趋势[J]. 中国防痨杂志, 2023, 45(2): 181-187.
[9]	戴振威, 张浩然, 荆舒, 肖伟军, 王浩, 黄依漫, 陈旭, 付佳琪, 吴奕锦, 高磊, 苏小游. 农村地区中老年2型糖尿病合并结核分枝杆菌潜伏感染者正念水平对心理健康的影响[J]. 中国防痨杂志, 2023, 45(2): 188-194.
[10]	周燕, 周萌, 彭军, 段琼红, 陈军, 周美兰, 张云侠, 梁军. 耐多药肺结核家庭内传播情况分析[J]. 中国防痨杂志, 2023, 45(2): 195-199.
[11]	陈堃, 林淑芳, 戴志松, 陈代权, 陈江芬. 福建省青少年结核病防治核心知识知晓情况及其对就诊延迟风险的影响[J]. 中国防痨杂志, 2023, 45(2): 200-207.
[12]	曲芸墨, 丁鑫园, 闫玫漪, 郭晓鹏, 孙义成. CRISPR基因组编辑技术在结核分枝杆菌中的研究进展及应用[J]. 中国防痨杂志, 2023, 45(2): 208-214.
[13]	王彦斌, 刘纯纯, 郝文嘉, 古颖春. 结核性心包炎合并心包结核瘤一例[J]. 中国防痨杂志, 2023, 45(2): 218-221.
[14]	姚利, 刘小玉, 蒋钰辉, 金武, 戴希勇, 杜鹃. 一例耐多药肠结核合并肠梗阻的手术治疗[J]. 中国防痨杂志, 2023, 45(2): 222-224.
[15]	王前, 王嘉, 李玉红, 刘二勇, 周林. 重视儿童结核病防治关爱儿童健康[J]. 中国防痨杂志, 2023, 45(1): 1-5.